Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.31 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | ESRRG | P62508 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4252283 | 1.00 | ESR1 (0.47) | ESR1OPRM1OPRD1CPT1BELANE | |
| SCHEMBL3469203 | 0.80 | ESR1 (0.54) | ESR1OPRM1CPT1BSMN1; SMN2 | |
| SCHEMBL3467939 | 0.80 | ESR1 (0.47) | ESR1OPRM1OPRD1CPT1BELANE | |
| SCHEMBL6506839 | 0.80 | ESR1 (0.47) | ESR1OPRM1OPRD1CPT1BELANE | |
| SCHEMBL3468121 | 0.77 | ESR1 (0.48) | ESR1 | |
| SCHEMBL3468119 | 0.77 | ESR1 (0.48) | ESR1 | |
| SCHEMBL3469207 | 0.74 | CA1 (0.57) | ESR1SMN1; SMN2 | |
| SCHEMBL3468043 | 0.73 | ESR1 (0.48) | ESR1HTTSMN1; SMN2 | |
| SCHEMBL3468865 | 0.72 | ESR1 (0.54) | ESR1 | |
| SCHEMBL3468864 | 0.72 | ESR1 (0.54) | ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7569601-B2 | Cycloalkylidene compounds as modulators of estrogen receptor | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-04 | — | — | US | disclosed |
| US-20070213348-A1 | Chemical Compounds | BRITTON JONATHAN E | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213348-A1 | Chemical Compounds | GPER1, ESR2, ESR1 | ESR1 3/4885OPRM1 211/4885OPRD1 235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.